Daina Graybosch
Stock Analyst at Leerink Partners
(0.81)
# 3,644
Out of 4,711 analysts
117
Total ratings
34.48%
Success rate
-13.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.03 | +94.17% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.50 | +100.00% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $3.14 | +473.25% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $75.54 | -48.37% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.93 | +223.17% | 10 | Feb 24, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $120 → $122 | $98.05 | +24.43% | 18 | Feb 3, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $1.10 | +1,172.73% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.68 | +495.24% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $1.19 | +4,942.02% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.05 | +339.02% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $15.50 | +145.16% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.08 | +57.48% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $113.08 | +98.09% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.37 | +1,165.82% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $7.42 | +695.15% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.59 | +969.18% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.53 | +488.24% | 4 | Feb 25, 2022 |
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.03
Upside: +94.17%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.50
Upside: +100.00%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $3.14
Upside: +473.25%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $75.54
Upside: -48.37%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.93
Upside: +223.17%
Merck & Co.
Feb 3, 2023
Maintains: Outperform
Price Target: $120 → $122
Current: $98.05
Upside: +24.43%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $1.10
Upside: +1,172.73%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.68
Upside: +495.24%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $1.19
Upside: +4,942.02%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.05
Upside: +339.02%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $15.50
Upside: +145.16%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.08
Upside: +57.48%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $113.08
Upside: +98.09%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.37
Upside: +1,165.82%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $7.42
Upside: +695.15%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.59
Upside: +969.18%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.53
Upside: +488.24%